Tissue galectin-3 as a potential prognostic biomarker in type 2 diabetes patients with hepatocellular carcinoma: in vitro and in silico approaches
Abstract
Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia, generating circulating glycated albumin (GA). The development and progression of liver cancer, and more specifically hepatocellular carcinoma (HCC), are increased in patients with T2D. To facilitate early diagnosis and appropriate therapeutic strategies, we sought to identify novel HCC biomarkers in these patients by investigating the biological impact of GA on HepG2 and metastatic HuH7 HCC cell lines. After treatment with various concentrations (25–200 µg/mL) of methylglyoxal-derived GA, cell viability, migration, and invasion were assessed, respectively, by CellTiter-Glo ® , scratch assay, and Matrigel™-coated Transwell™ inserts. The expression of signaling and oncology-related proteins was monitored using Western blot and protein array analyses. GA significantly and dose-dependently modulated cell viability, wound healing, and oncogenic p-ERK according to a bell-shaped curve, compared to untreated cells, the control. At 100 µg/mL, GA significantly stimulated cell invasion and augmented ribosomal protein S6 phosphorylation, EpCAM, and galectin-3 expression in metastatic HuH7 cells, mainly to a lesser extent in HepG2 cells. TCGA database analysis revealed, unlike EpCAM, a positive correlation between the high expression levels of genes encoding pS6 kinase and galectin-3, and liver cancer patients’ high BMI, advanced stages of HCC, metastatic status, and poor overall survival. By immunohistochemical staining, only galectin-3 was detected significantly in HCC tissues from T2D Saudi patients compared to their non-diabetic counterparts. A larger cohort is needed to evaluate galectin-3 expression as a potential biomarker and its prognostic values in T2D patients with HCC.
Related
- Prognostic significance of KIF2C and its association with lactate metabolism in hepatocellular carcinoma
- Integrating ferroptosis and the tumor-immune gene mutations interface: a novel lenvatinib resistance prognostic signature with YWHAB-related immunotherapeutic correlates in hepatocellular carcinoma
- PIVKA-II and hematological parameters in hepatocellular carcinoma and non-malignant chronic liver disease: A case-control biomarker comparison in a hepatitis-endemic population
- Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report
- Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
BibTeX
@article{matounasri2026tissue,
title = {{Tissue galectin-3 as a potential prognostic biomarker in type 2 diabetes patients with hepatocellular carcinoma: in vitro and in silico approaches}},
author = {Sabine Matou-Nasri and Amina Munye and Hamad Al-Eidi and Rehab AlRoshody and Ahood H. Alsayed and Mariam K. Alamoudi and Abdulmonem A. Alsaleh and Majed M. Alotaibi and Ali A. Alfayez and Maram Aldawood and Fatimah Alanazi and Yara Almihmadi and Hadel Alsaran and Haitham S. Alkadi},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-72650-4},
url = {https://www.nature.com/articles/s41598-026-72650-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tissue galectin-3 as a potential prognostic biomarker in type 2 diabetes patients with hepatocellular carcinoma: in vitro and in silico approaches
AU - Sabine Matou-Nasri
AU - Amina Munye
AU - Hamad Al-Eidi
AU - Rehab AlRoshody
AU - Ahood H. Alsayed
AU - Mariam K. Alamoudi
AU - Abdulmonem A. Alsaleh
AU - Majed M. Alotaibi
AU - Ali A. Alfayez
AU - Maram Aldawood
AU - Fatimah Alanazi
AU - Yara Almihmadi
AU - Hadel Alsaran
AU - Haitham S. Alkadi
PY - 2026
DA - 2026/10/05
JO - Scientific Reports
DO - 10.1038/s41598-026-72650-4
UR - https://www.nature.com/articles/s41598-026-72650-4
AB - Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia, generating circulating glycated albumin (GA). The development and progression of liver cancer, and more specifically hepatocellular carcinoma (HCC), are increased in patients with T2D. To facilitate early diagnosis and appropriate therapeutic strategies, we sought to identify novel HCC biomarkers in these patients by investigating the biological impact of GA on HepG2 and metastatic HuH7 HCC cell lines. After treatment with various concentrations (25–200 µg/mL) of methylglyoxal-derived GA, cell viability, migration, and invasion were assessed, respectively, by CellTiter-Glo ® , scratch assay, and Matrigel™-coated Transwell™ inserts. The expression of signaling and oncology-related proteins was monitored using Western blot and protein array analyses. GA significantly and dose-dependently modulated cell viability, wound healing, and oncogenic p-ERK according to a bell-shaped curve, compared to untreated cells, the control. At 100 µg/mL, GA significantly stimulated cell invasion and augmented ribosomal protein S6 phosphorylation, EpCAM, and galectin-3 expression in metastatic HuH7 cells, mainly to a lesser extent in HepG2 cells. TCGA database analysis revealed, unlike EpCAM, a positive correlation between the high expression levels of genes encoding pS6 kinase and galectin-3, and liver cancer patients’ high BMI, advanced stages of HCC, metastatic status, and poor overall survival. By immunohistochemical staining, only galectin-3 was detected significantly in HCC tissues from T2D Saudi patients compared to their non-diabetic counterparts. A larger cohort is needed to evaluate galectin-3 expression as a potential biomarker and its prognostic values in T2D patients with HCC.
SN - 2045-2322
ER -